Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit

Journal of Hospital Infection

Volumn 75, Issue 1, 2010, Pages 23-27

  Jacoby, T S ^a   Kuchenbecker, R S ^a   dos Santos, R P ^a   Magedanz, L ^b   Guzatto, P ^b   Moreira, L B ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antimicrobial use; Drug resistance; Hospital infection; Microbial resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN;

ACINETOBACTER; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATE; BLADDER CATHETERIZATION; CENTRAL VENOUS CATHETERIZATION; DRUG UTILIZATION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREVALENCE; SURGICAL PROCEDURES, OPERATIVE; YOUNG ADULT;

EID: 77951622838     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2009.11.021     Document Type: Article

References (29)

1. Eggimann P., Pittet D. Infection control in the ICU. Chest 2001, 120:2059-2093.
2. Weber D.J., Raasch R., Rutala W.A. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest 1999, 115:34S-41S.
3. Digiovine B., Chenoweth C., Watts C., Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999, 160:976-981.
4. Buke C., Armand-Lefevre L., Lolom I., et al. Epidemiology of multidrug-resistant bacteria in patients with long hospital stays. Infect Control Hosp Epidemiol 2007, 28:1255-1260.
5. Gales A.C., Jones R.N., Andrade S.S., Sader H.S. Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002). Mem Inst Oswaldo Cruz 2005, 100:571-577.
6. Lee N.Y., Lee H.C., Ko N.Y., et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007, 28:713-719.
7. Ruttimann S., Keck B., Hartmeier C., Maetzel A., Bucher H.C. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004, 38:348-356.
8. Hsueh P.R., Chen W.H., Luh K.T. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005, 26:463-472.
9. López-Lozano J.M., Monnet D.L., Yagüe A., et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents 2000, 14:21-31.
10. Jean S.S., Hsueh P.R., Lee W.S., et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009, 33:266-271.
11. Dellit T.H., Owens R.C., McGowan J.E., Infectious Diseases Society of America; Society for Healthcare Epidemiology of America, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
12. Polk R.E., Fox C., Mahoney A., Letcavage J., MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007, 44:664-670.
13. Natsch S., Hekster Y.A., de Jong R., Heerdink E.R., Herings R.M., van der Meer J.W. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis 1998, 17:20-24.
14. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement 2007, CLSI, Wayne, PA.
15. Hindler J.F., Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 2007, 44:867-873.
16. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections. Am J Infect Control 1988, 1988(16):128-140.
17. Siegel J.D., Rhinehart E., Jackson M., Chiarello L., Healthcare Infection Control Practices Advisory Committee Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007, 35:S165-S193.
18. Rogues A.M., Dumartin C., Amadéo B., et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007, 28:1389-1395.
19. Lucet J.C., Chevret S., Decre D., et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996, 22:430-436.
20. Harbarth S., Harris A.D., Carmeli Y., Samore M.H. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 2001, 33:1462-1468.
21. Olofsson S.K., Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007, 45(Suppl. 2):S129-S136.
22. Levin P.D., Fowler R.A., Guest C., Sibbald W.J., Kiss A., Simor A.E. Risk factors associated with resistance to ciprofloxacin in clinical bacterial isolates from intensive care unit patients. Infect Control Hosp Epidemiol 2007, 28:331-336.
23. Nseir S., Di Pompeo C., Soubrier S., et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005, 33:283-289.
24. Tacconelli E., De Angelis G., Cataldo M.A., Pozzi E., Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008, 61:26-38.
25. Wattal C., Joshi S., Sharma A., Oberoi J.K., Prasad K.J. Prescription auditing and antimicrobial resistance at a tertiary care hospital in New Delhi, India. J Hosp Infect 2005, 59:156-158.
26. Climo M., Diekema D., Warren D.K., et al. Prevalence of the use of central venous access devices within and outside of the intensive care unit: results of a survey among hospitals in the prevention epicenter program of the Centers for Disease Control and Prevention. Infect Control Hosp Epidemiol 2003, 24:942-945.
27. Marschall J., Leone C., Jones M., Nihill D., Fraser V.J., Warren D.K. Catheter-associated bloodstream infections in general medical patients outside the intensive care unit: a surveillance study. Infect Control Hosp Epidemiol 2007, 28:905-909.
28. Vonberg R.P., Behnke M., Geffers C., et al. Device-associated infection rates for non-intensive care unit patients. Infect Control Hosp Epidemiol 2006, 27:357-361.
29. Hartley D.M., Furuno J.P., Wright M.O., Smith D.L., Perencevich E.N. The role of institutional epidemiologic weight in guiding infection surveillance and control in community and hospital populations. Infect Control Hosp Epidemiol 2006, 27:170-174.